Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesCardiologyPremera Bluecross cholesterol policy update: Cover…
    Ask Trek AI about this page
    ModifiedPremera BluecrossPolicy 5.01.558

    Pharmacologic Treatment of High Cholesterol

    Customize your policy alerts

    Sign up for Premera Bluecross Policy 5.01.558 alerts

    Get alerted when Policy 5.01.558 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity and site-of-service review for pharmacologic treatments used to lower cholesterol (including injectable and IV agents) for Premera members, detailing coverage criteria, dosing limits, and prior authorization/administration site requirements for adults and selected pediatric ages.

    Policy Summary
    PayerPremera Bluecross
    PolicyPharmacologic Treatment of High Cholesterol
    Policy CodePolicy 5.01.558
    Change TypeAdded multiple agents and revised age/indication criteria
    Effective DateAug 1, 2026
    Last ReviewJul 14, 2026
    Next Review DateJul 14, 2026
    Key ActionObtain prior authorization confirming diagnosis, baseline LDL-C or TG thresholds, and evidence of maximally tolerated statin therapy (or documented statin intolerance) before initiating listed injectable or specialty agents.
    SourceLink
    POLICY UPDATE CHANGES

    Added coverage criteria for Tryngolza (olezarsen) for the treatment of familial chylomicronemia syndrome.

    Added coverage criteria for Lerochol (lerodalcibep-liga) for treatment of HeFH and hypercholesterolemia.

    Added coverage criteria for Redemplo (plozasiran) for the treatment of familial chylomicronemia syndrome.

    Updated age and indication criteria for multiple agents (Leqvio, Evkeeza, Praluent, Repatha, Juxtapid) and changed some indications from 'primary hyperlipidemia' to 'hypercholesterolemia'.

    Updated criteria for Leqvio (inclisiran) HeFH age requirement from 18 years to 12 years or older and added coverage criteria for treatment of HoFH.

    Updated Evkeeza age requirement to 1 year and clarified prior Repatha requirement for individuals aged 10 years and older.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3
    New agents added
    52%LDL-C reductions (inclisiran)
    −59.4%Tryngolza 12‑mo TG change
    3 yearsTypical approval period
    non‑Medicare AdvantagePolicy applies to

    Coverage Criteria and Medical Necessity

    Leqvio (inclisiran) — ASCVD

    Covered when ALL of the following are met

    Leqvio for ASCVD: Individual aged >=18 years AND has clinical ASCVD (prior MI/acute coronary syndrome, angina, prior stroke/TIA, PAD of atherosclerotic origin, or prior coronary/arterial revascularization) AND has tried one high-intensity statin for >=8 continuous weeks with LDL-C >=70 mg/dL OR is statin intolerant as defined (rhabdomyolysis to one statin OR skeletal-muscle symptoms after trying both rosuvastatin AND atorvastatin which resolved upon discontinuation) AND has tried and had inadequate response or intolerance to Repatha (evolocumab) AND Leqvio (inclisiran) is prescribed by or in consultation with a cardiologist, endocrinologist, or clinician focused on lipid/cardiovascular risk AND dosing limited to 284 mg at initiation, at 3 months, then every 6 months thereafterage >=18; LDL-C >=70 mg/dL

    Site-of-service review applies for administration; document prior therapies and LDL-C values.

    Leqvio (inclisiran) — HeFH

    Covered when ALL of the following are met

    Leqvio for HeFH: Individual aged >=12 years AND meets HeFH diagnostic criteria (untreated LDL-C >=190 mg/dL OR genetic confirmation OR Dutch Lipid Network score >5 OR Simon Broome criteria) AND has tried one high-intensity statin for >=8 continuous weeks with LDL-C >=70 mg/dL OR is statin intolerant as defined AND has tried and had inadequate response or intolerance to Repatha (evolocumab) AND Leqvio (inclisiran) is prescribed by or in consultation with a cardiologist, endocrinologist, or clinician focused on lipid/cardiovascular risk AND dosing per label (284 mg at onset, 3 months, then every 6 months)age >=12; LDL-C >=190 mg/dL (untreated) or LDL-C >=70 mg/dL after statin per pathway

    Accepts genetic or clinical scoring (Simon Broome/Dutch) to establish HeFH.

    Leqvio (inclisiran) — HoFH

    Covered when ALL of the following are met

    Leqvio for HoFH: Individual aged >=12 years AND meets HoFH criteria (untreated LDL-C >400 mg/dL OR treated LDL-C >=300 mg/dL OR genetic confirmation of two pathogenic alleles in LDLR/APOB/PCSK9/LDLRAP1) AND has tried one high-intensity statin for >=8 continuous weeks with LDL-C >=70 mg/dL OR is statin intolerant as defined AND has tried and had inadequate response or intolerance to Repatha (evolocumab) AND Leqvio (inclisiran) is prescribed by or in consultation with a cardiologist, endocrinologist, or clinician focused on lipid/cardiovascular risk AND dosing per label (284 mg at onset, 3 months, then every 6 months)age >=12; LDL-C >400 mg/dL untreated or >=300 mg/dL treated

    HoFH requires high LDL thresholds or genetic confirmation; document prior maximal tolerated therapy.

    Icosapent ethyl — cardiovascular risk reduction

    Covered when ALL of the following are met

    Icosapent ethyl for CV risk reduction: Individual aged >=18 years AND fasting triglycerides >=150 mg/dL AND on moderate- or high-intensity statin therapy unless not tolerated AND either has established cardiovascular disease OR has diabetes plus >=2 additional CV risk factors (family history of premature ASCVD, tobacco use, hypertension on medication [BP >=130/80], or renal dysfunction defined as eGFR 15-59 mL/min/1.73m2 or CrCl <60 mL/min) AND dose limited to 4 g/dayage >=18; TG >=150 mg/dL

    Document statin use or intolerance and risk-factor criteria; REDUCE-IT trial population informed criteria.

    Icosapent ethyl — severe hypertriglyceridemia (generic)

    Covered when ALL of the following are met

    Generic icosapent ethyl for severe HTG: Individual aged >=18 years AND triglycerides >=500 mg/dL AND has tried and had inadequate response or intolerance to fenofibrate OR a prescription niacin extended-release product AND dose limited to 4 g/dayTG >=500 mg/dL

    Step therapy requires prior fibrate or niacin trial; document prior medications and TG values.

    Evkeeza (evinacumab-dgnb) and Juxtapid (lomitapide) — HoFH

    Covered when ALL of the following are met

    Evkeeza for HoFH: Evkeeza (evinacumab-dgnb): individual aged >=1 year AND meets HoFH criteria (untreated LDL-C >400 mg/dL OR treated LDL-C >=300 mg/dL OR genetic confirmation of two mutant alleles) AND has tried one high-intensity statin for >=8 continuous weeks with LDL-C >=70 mg/dL OR is statin intolerant as defined AND for individuals aged >=10 years have tried and had inadequate response or intolerance to Repatha (evolocumab) AND Evkeeza is prescribed by or in consultation with a cardiologist, endocrinologist, or clinician focused on lipid/cardiovascular risk AND dose limited to 15 mg/kg IV every 4 weeksage >=1 for Evkeeza; LDL-C thresholds as above

    ELIPSE-HoFH trial used 15 mg/kg IV q4w; avoid in pregnancy per prescribing information.

    Juxtapid for HoFH: Juxtapid (lomitapide): individual aged >=2 years AND meets HoFH criteria (untreated LDL-C >400 mg/dL OR treated LDL-C >=300 mg/dL OR genetic confirmation of two mutant alleles) AND has tried one high-intensity statin for >=8 continuous weeks with LDL-C >=70 mg/dL OR is statin intolerant as defined AND for individuals aged >=10 years have tried and had inadequate response or intolerance to Repatha (evolocumab) AND Juxtapid is prescribed by or in consultation with a cardiologist, endocrinologist, or clinician focused on lipid/cardiovascular risk AND dose limited to 60 mg daily with quantity limits per capsule strengthage >=2 for Juxtapid; dose limit 60 mg/day

    Lerochol (lerodalcibep) and other PCSK9/PCSK9-like agents — HeFH and hypercholesterolemia

    Covered when ALL of the following are met

    Lerochol for HeFH: Individual aged >=18 years AND meets HeFH criteria (untreated LDL-C >=190 mg/dL OR genetic confirmation OR Dutch Lipid Network score >5 OR Simon Broome criteria) AND has tried one high-intensity statin for >=8 continuous weeks with LDL-C remains >=100 mg/dL OR is statin intolerant as defined AND has tried and had inadequate response or intolerance to Repatha (evolocumab) AND Lerochol (lerodalcibep-liga) is prescribed by or in consultation with a cardiologist, endocrinologist, or clinician focused on lipid/cardiovascular risk AND dose limited to 300 mg once monthlyage >=18; LDL-C >=190 mg/dL for HeFH

    Accepts genetic or clinical scoring to establish HeFH; trials enrolled patients on maximally tolerated statins.

    Lerochol for hypercholesterolemia: Individual aged >=18 years AND either CAC >=100 Agatston units or >=75th percentile OR 10-year ASCVD risk >=7.5% OR has diabetes AND has tried one high-intensity statin for >=8 continuous weeks with LDL-C remains >=100 mg/dL OR is statin intolerant as defined AND has tried and had inadequate response or intolerance to Repatha (evolocumab) AND Lerochol is prescribed by or in consultation with a cardiologist, endocrinologist, or clinician focused on lipid/cardiovascular riskCAC >=100 or ASCVD risk >=7.5%

    Nexletol / Nexlizet (bempedoic acid ) - ASCVD, HeFH, hypercholesterolemia

    Covered when ALL of the following are met

    Nexletol/Nexlizet for ASCVD: Individual aged >=18 years AND has clinical ASCVD (prior MI/ACS, angina, prior stroke/TIA, PAD, or prior coronary/arterial revascularization) AND has tried one high-intensity statin for >=8 continuous weeks with LDL-C >=70 mg/dL OR is statin intolerant as defined AND prescribed by or in consultation with a cardiologist, endocrinologist, or clinician focused on lipid/cardiovascular risk AND dose limited to 180 mg bempedoic acid dailyage >=18; LDL-C >=70 mg/dL; dose 180 mg/day

    Initial approval typically 3 years; reauthorization requires documentation of continued clinical benefit.

    Nexletol/Nexlizet for HeFH or hypercholesterolemia: Individual aged >=18 years AND meets HeFH (untreated LDL-C >=190 mg/dL or genetic/clinical criteria) or hypercholesterolemia criteria (CAC >=100 Agatston or >=75th percentile OR 10-year ASCVD risk >=7.5% OR diabetes) AND has tried one high-intensity statin for >=8 continuous weeks with LDL-C remains >=100 mg/dL for hypercholesterolemia or >=70 mg/dL for ASCVD/HeFH OR is statin intolerant as defined AND dose limited to 180 mg bempedoic acid dailyage >=18; dose 180 mg/day

    Documentation of prior statin trial or intolerance required; initial approval 3 years.

    Lovaza / omega-3-acid ethyl esters — severe hypertriglyceridemia

    Covered when ALL of the following are met

    Lovaza for severe HTG: Individual aged >=18 years AND triglycerides >=500 mg/dL AND has tried and had an inadequate response or intolerance to generic omega-3-acid ethyl esters AND dose limited to 4 g/day (single or split dosing)TG >=500 mg/dL

    Step therapy with generic omega-3 required; document prior TG measurements and prior product trials.

    Nexletol / Nexlizet (bempedoic acid ) - hypercholesterolemia

    May be considered medically necessary when ALL of the following are met

    Age: Individual is aged 18 years or older
    Risk threshold: Has CAC >=100 Agatston units or >=75th percentile OR 10-year ASCVD risk >=7.5% OR has diabetes
    Prior therapy: Tried one high-intensity statin for >=8 continuous weeks with LDL-C >=100 mg/dL OR is statin intolerant as defined (rhabdomyolysis to one statin OR skeletal-muscle symptoms after trying both rosuvastatin AND atorvastatin which resolved upon discontinuation)LDL-C >=100 mg/dL if on statin

    Dose limited to 180 mg bempedoic acid daily

    Praluent (alirocumab) — ASCVD, HeFH, HoFH, hypercholesterolemia

    May be considered medically necessary when ALL of the following are met (drug-specific for each indication)

    Age for indications: Individual is aged 18 years or older for ASCVD/hypercholesterolemia; age thresholds vary by indication (eg, HeFH age >=8 years; Repatha HeFH/HoFH age >=10 years) per specific indication sections

    See indication-specific nodes for exact age cutoffs.

    ASCVD criteria: History of MI/acute coronary syndrome OR angina OR prior stroke/TIA OR PAD of atherosclerotic origin OR prior coronary/arterial revascularization
    Risk threshold for hypercholesterolemia: CAC >=100 Agatston units or >=75th percentile OR 10-year ASCVD risk >=7.5% OR has diabetes
    Prior therapy/LDL thresholds: Tried one high-intensity statin for >=8 continuous weeks with LDL-C remains >=70 mg/dL (ASCVD/HeFH/HoFH) or >=100 mg/dL (some hypercholesterolemia criteria) OR statin intolerance as defined

    Repatha (evolocumab) — ASCVD, HeFH, HoFH, hypercholesterolemia

    May be considered medically necessary when ALL of the following are met (drug-specific per indication)

    Age: Individual is aged 18 years or older for ASCVD/hypercholesterolemia; age 10 years or older for HeFH and HoFH indications per agent-specific sections
    ASCVD criteria: History of MI/acute coronary syndrome OR angina OR prior stroke/TIA OR PAD OR prior coronary/arterial revascularization
    Risk threshold for hypercholesterolemia: CAC >=100 Agatston units or >=75th percentile OR 10-year ASCVD risk >=7.5% OR has diabetes
    Prior therapy/LDL thresholds: Tried one high-intensity statin for >=8 continuous weeks with LDL-C remains >=70 mg/dL (ASCVD/HeFH/HoFH) or LDL-C >=100 mg/dL for some hypercholesterolemia criteria OR statin intolerance as definedLDL-C >=70 or >=100 mg/dL depending on indication

    Redemplo (plozasiran) and Tryngolza (olezarsen) — Familial chylomicronemia syndrome (FCS)

    May be considered medically necessary when ALL of the following are met

    Age: Individual is aged >=18 years
    Triglyceride threshold: Fasting serum triglyceride >=880 mg/dLTG >=880 mg/dL
    Genetic/clinical confirmation: Genetic mutation in LPL-pathway genes (APOC2, APOA5, GPIHBP1, LMF1, LPL) OR evidence of low/absent LPL activity (<=20% normal) OR history of recurrent pancreatitis not due to alcohol/cholelithiasis OR recurrent hospitalizations for severe abdominal pain OR documented childhood pancreatitis OR family history of hypertriglyceridemia-induced pancreatitis

    Document genetic or clinical confirmation to support FCS diagnosis.

    Diet and prescriber:

    Vascepa (icosapent ethyl) — cardiovascular risk reduction and severe hypertriglyceridemia

    May be considered medically necessary when the following criteria are met

    Age: Individual is aged >=18 years
    Cardiovascular risk reduction criteria: Triglycerides >=150 mg/dL AND individual is on moderate- or high-intensity statin therapy unless not tolerated AND either established CVD OR diabetes plus >=2 additional CV risk factors (family history of premature ASCVD, tobacco use, hypertension on meds [BP >=130/80], or renal dysfunction defined as eGFR 15-59 mL/min/1.73m2) AND has tried and had an inadequate response or intolerance to generic icosapent ethyl AND dose limited to 4 g/dayTG >=150 mg/dL

    Document statin therapy or intolerance, prior generic icosapent ethyl trial, and risk-factor criteria.

    Severe hypertriglyceridemia criteria: Triglycerides >=500 mg/dL AND has tried and had an inadequate response or intolerance to generic icosapent ethyl AND dose limited to 4 g/dayTG >=500 mg/dL

    Zetia (ezetimibe), niacin, fibrates, brand statins — trials and prior use

    May be considered medically necessary when trials of generic alternatives have been attempted and failed or were not tolerated

    Ezetimibe: Individual has had a trial and inadequate response or intolerance to generic ezetimibe

    Initial approval 3 years; reauthorization based on continued clinical benefit.

    Niacin (eg, Niacor) considered medically necessary when individual had trial and inadequate response or intolerance to generic niacin
    Brand fibrates/statins: Brand fenofibrate or other brand agents may be considered when trial and inadequate response or intolerance to generic equivalents (eg, generic fenofibrate and gemfibrozil) documented

    Initial approval typically 3 years; reauthorization requires documentation of clinical benefit.

    Statin intolerance due to myopathy or transaminitis

    Medically necessary substitutions for statin intolerance when ALL criteria are met

    Myopathy intolerance: Individual has intolerable symptoms AND provider has ruled out other potential causes for myopathy (eg, interacting medications, hypothyroidism, reduced renal/hepatic function, steroid myopathy, vitamin D deficiency, primary muscle disease)

    Document evaluation and symptom resolution after statin discontinuation when applicable.

    Transaminitis intolerance: Provider has ruled out other causes for transaminitis, transaminitis persists beyond 12 weeks from statin start, AND individual failed reduction of statin therapy

    Document LFT trends and therapeutic attempts to reduce statin dose.

    Advanced lipid-lowering therapy (e.g., PCSK9 inhibitors) — initiation criteria

    Coverage and medical necessity for PCSK9 inhibitors and other advanced lipid-lowering therapies are tied to documented inadequate LDL-C response on maximally tolerated statin therapy and dosing/titration guidance:

    PCSK9 therapy initiation: Patient is on a maximally tolerated dose of statin (with or without other lipid-modifying therapy) AND requires additional LDL-C reduction as documented by LDL-C levelsMeasure LDL-C 4-8 weeks after initiation/titration

    Dosing and titration guidance (eg, alirocumab 75 mg Q2W with up-titration to 150 mg Q2W if inadequate) and response assessment timing described.

    HeFH diagnosis evidence: Diagnosis of HeFH may be established by genotyping or clinical criteria (Simon Broome or Dutch Lipid Network criteria)

    Use diagnostic scoring or genetic confirmation to support coverage eligibility.

    Initial therapy coverage criteria

    Covered when ALL of the following are consistent with trial populations and drug labeling

    Population and prior therapy: Member has HeFH or clinical ASCVD and is on a maximally tolerated dose of statin with or without other lipid-modifying therapyas per trial entry

    Trials for alirocumab, evolocumab, and inclisiran required maximally tolerated statin; inclisiran trials excluded individuals on PCSK9 inhibitors.

    LDL-C or lipid threshold: Member has baseline LDL-C (or triglyceride criteria for icosapent ethyl) indicating need for additional lipid loweringExamples vary by agent (eg, inclisiran mean baseline LDL-C ~101-153 mg/dL in trials); specific numeric thresholds depend on agent and indication

    Use agent-specific numeric thresholds documented in policy sections.

    Dosing and administration: Prescribed dosing consistent with product regimen used in pivotal trials (eg, alirocumab 75-150 mg Q2W, evolocumab 140 mg Q2W or 420 mg monthly, inclisiran 284 mg Day 1/90 then q6 months, icosapent ethyl 4 g/day)

    Trial-supported candidate criteria (informational)

    Therapies supported by pivotal trials in specified populations:

    Evkeeza (evinacumab): Evidence supports use in HoFH as studied: IV evinacumab 15 mg/kg every 4 weeks added to maximally tolerated lipid-lowering therapy producing ~47%–49% placebo-adjusted LDL-C reduction at 24 weeksHoFH diagnosis; ongoing maximally tolerated therapy

    ELIPSE-HoFH: 65 participants; consistent LDL reduction across background therapies.

    Lerochol (lerodalcibep): Trials in adults with HeFH or ASCVD on maximally tolerated statin therapy showed ~50%–59% placebo-adjusted LDL-C reductions at 24–52 weeks, supporting its use for additional LDL-C lowering while on background therapyMaximally tolerated statin therapy; need for additional LDL-C lowering

    Two 52-week randomized trials (N=1,844 combined) reported ~50–55% LDL-C reductions versus placebo.

    Nexletol/Nexlizet (bempedoic acid): CLEAR program showed placebo-corrected LDL-C reductions (eg, ~17%–21% at 12 weeks) when added to maximally tolerated statins or in statin-intolerant populations, supporting use for LDL-C lowering in indicated populations

    Tryngolza (olezarsen) - Initial coverage criteria (excerpt)

    Selected coverage updates and criteria clarifications (excerpted):

    Tryngolza coverage update: Tryngolza (olezarsen) added for familial chylomicronemia syndrome; must be prescribed by or in consultation with an endocrinologist; medication will not be used in combination with Redemplo (plozasiran); diagnosis must be confirmed by at least one additional criterion (genetic testing or qualifying clinical diagnosis)age >=18 and fasting TG >=880 mg/dL per FCS criteria in policy

    See full Tryngolza/Redemplo sections for detailed numeric and stepwise criteria.

    Age and indication updates (excerpt)

    Revisions to age and indication criteria for multiple agents:

    Leqvio (inclisiran): HeFH age requirement changed from 18 years to 12 years or older; coverage expanded to include HoFH treatmentage >=12 for HeFH; HoFH added

    See Leqvio-specific section for LDL thresholds and prior therapy requirements.

    Evkeeza (evinacumab-dgnb): Age requirement changed to 1 year or older and clarified that individuals aged >=10 years should have tried Repatha (evolocumab) firstage >=1
    Praluent and Repatha: Praluent HeFH coverage age updated to >=8 years; Repatha HeFH/HoFH coverage age updated to >=10 yearsPraluent age >=8; Repatha age >=10

    General coverage stance and agent-specific criteria

    Covered when criteria specific to each agent are met as detailed in the policy

    Policy scope: Coverage applies to pharmacologic treatments for hyperlipidemia, familial hypercholesterolemia, and severe hypertriglyceridemia when member meets the agent-specific criteria and benefit limits

    This policy does not apply to Medicare Advantage members; document required clinical elements for prior authorization.

    Newly added agent criteria (summary)

    Recent additions and updates effective 2026-08-01:

    Lerochol: Coverage criteria added for Lerochol (lerodalcibep-liga) for HeFH and hypercholesterolemia; see Lerochol section for age, prior therapy, and specialist requirements

    Dosing and LDL thresholds specified in Lerochol section.

    Redemplo: Coverage criteria added for Redemplo (plozasiran) for familial chylomicronemia syndrome; see Redemplo section for fasting TG, genetic/clinical confirmation, dietary management, and endocrinologist prescriber requirement

    Policy clarifies Tryngolza/Redemplo cannot be used together.

    Site-of-service rules require that infusion or injection administration occur in medically appropriate locations. Preferred medically necessary sites include a physician's office, infusion center, or home infusion when available; hospital-based outpatient settings and outpatient hospital IV infusion departments are considered medically necessary only when the policy's site-of-service criteria are met (for example, no infusion center within 50 miles or no contracted home infusion agency, or when the member has a clinical condition that increases the risk of complications). If the site-of-service criteria in this policy are not satisfied, the hospital outpatient IV infusion department and hospital-based outpatient settings are considered not medically necessary for infusion or injectable therapy services.

    Uses of the listed medications that are not specifically enumerated in the Medical Necessity sections are classified as investigational or not medically necessary and may be denied. The policy explicitly lists multiple agents whose indications outside the medical necessity sections are considered investigational; similarly, specified branded and discontinued products and other uses not included in the medical necessity criteria are considered not medically necessary.

    Benefit assignment varies by agent: most drugs in this policy are managed through the pharmacy benefit. Exceptions managed through the medical benefit include Evkeeza (evinacumab-dgnb) and Leqvio (inclisiran). Redemplo (plozasiran) and Tryngolza (olezarsen) may be managed through both pharmacy and medical benefits. Applicable HCPCS/administration coding (for example J1305, J1306, J3490) and prior authorization requirements should be followed based on benefit assignment.

    Pivotal trials for some agents excluded individuals already receiving PCSK9 inhibitors; for example, inclisiran (LEQVIO) trials excluded participants on PCSK9 inhibitors. This trial-design detail informs step/eligibility logic: documentation should show appropriate prior therapy or rationale (e.g., maximally tolerated statin with or without other lipid-modifying therapy) consistent with trial populations when requesting coverage.

    Evinacumab (Evkeeza) has a pregnancy/embryo-fetal toxicity caution in its safety information. The prescribing information notes the potential for fetal harm based on animal studies, and recommends obtaining a pregnancy test prior to initiating treatment and use of contraception during treatment and for at least 5 months after the last dose.

    Coverage criteria and references for several discontinued products were removed in recent updates. The policy updates note removal of coverage language for multiple discontinued agents (for example, certain discontinued statins and fibrates), reflecting that criteria for those products are no longer included in the policy.

    This medical policy does not apply to Medicare Advantage members. Coverage determinations under this policy are subject to the limits and conditions of the member's benefit plan, and providers should consult the member benefit booklet or customer service to confirm applicability and benefit limitations.

    If site-of-service criteria are not met for outpatient infusion or injection services, the request may be denied as not medically necessary. Examples of site-of-service criteria include distance to a local infusion center, availability of a contracted home infusion agency, or the presence of a clinical condition that increases infusion risk (e.g., unstable cardiac or pulmonary disease, unstable vascular access, or history of severe hypersensitivity).

    The policy includes a specific investigational/not medically necessary list: all uses of agents that are not included in the Medical Necessity sections are considered investigational or not medically necessary and may be denied. Additionally, certain branded products and specified agents are listed as not medically necessary when used for indications outside the policy's covered criteria.

    Requests that do not include required medical record documentation may be considered not medically necessary. The record must include office visit notes documenting the diagnosis, relevant history, physical examination, lipid panels, and a medication history to demonstrate that the coverage criteria are met.

    For some agents the intended use is to achieve long-term clinical outcomes, but the policy highlights where long-term outcome evidence is limited. For example, labels and trial summaries note limited evidence for long-term clinical outcome effects for PCSK9 inhibitors; coverage decisions focus on achieving specified lipid thresholds and documented LDL-C or triglyceride responses rather than assumed long-term outcome benefits.

    Some sections of the policy excerpts do not contain explicit 'not medically necessary' declarations. Historical updates (for example the 2018 and 2020 reviews) noted that added trial evidence did not change the medical necessity criteria, and several chunks in the record do not include new not-medically-necessary language.

    In the portions of the document reviewed, no new not-medically-necessary conditions were added; prior literature and update summaries indicate that trial outcomes reinforced existing criteria and did not create additional not-medically-necessary rules in these excerpts.

    Coverage under this policy is subject to member benefit limitations. Even when medical necessity criteria are met, services may be denied if they exceed the member's contract limits or are not a covered benefit. Providers should verify benefits and document necessity fully to minimize benefit-related denials.

    Prior Authorization, Documentation, and Billing Requirements

    Prior Authorization

    Prior authorization and site‑of‑service review

    Prior authorization and site-of-service review are required for listed injectable/IV agents (e.g., Leqvio/inclisiran); Leqvio is subject to site-of-service review and administration is limited to the medically appropriate site as described in policy (initial course/site-specific coverage for first 90 days or re-initiation after ≥6 months).

    • Leqvio (inclisiran) is subject to site-of-service review and may be covered in the most appropriate, safe, and cost‑effective site; initial course or re‑initiation after ≥6 months is covered for the first 90 days.
    • Prior authorization must demonstrate the drug‑specific medical necessity criteria are met (e.g., ASCVD/HeFH/HoFH criteria for inclisiran).
    Prior Authorization

    Prior authorization and applicable HCPCS

    Prior authorization is required per the drug‑specific medical necessity criteria; applicable HCPCS codes called out in the policy include J1305 (evinacumab), J1306 (inclisiran/Leqvio) and J3490 for unclassified drugs (used to report agents such as Redemplo or Tryngolza).

    Billing Codes, Thresholds, and Key Numeric Criteria

    HCPCS codesHCPCS
    J1305Injection, evinacumab-dgnb, (Evkeeza) 5 mg.
    J1306Injection, inclisiran, (Leqvio) 1 mg.
    J3490Unclassified drugs (use to report: Redemplo, Tryngolza)
    HCPCS codes for specialty injectables / unclassified drugsHCPCS
    J1305Injection, evinacumab-dgnb, (Evkeeza) 5 mg.
    J1306Injection, inclisiran, (Leqvio) 1 mg.
    J3490Unclassified drugs (use to report: Redemplo, Tryngolza)
    No explicit billing codes in these chunksmixed
    No codes listed
    Coronary artery calcium (CAC) score threshold
    CAC threshold>= 100 Agatston units or >= 75th percentile for age/gender/ethnicity
    Used for hypercholesterolemia coverageCAC >=100 or >=75th percentile can satisfy risk criteria for Leqvio, Lerochol, Repatha and other agents
    Alternative risk metricCalculated 10-year ASCVD risk >=7.5% may be used instead of CAC for some hypercholesterolemia indications
    Triglycerides (TG) numeric thresholds
    CV risk reduction threshold>= 150 mg/dL (used for icosapent ethyl cardiovascular risk-reduction eligibility)
    Severe hypertriglyceridemia treatment threshold

    Background, Definitions and Mechanisms

    Familial hypercholesterolemia (FH) is an inherited disorder characterized by defective clearance of LDL cholesterol, leading to markedly elevated LDL-C levels and accelerated atherosclerosis. First-line management includes lifestyle modification and statin therapy; when LDL-C remains elevated despite maximally tolerated statin therapy, or when statin intolerance is documented, non-statin pharmacologic agents (including PCSK9-targeted therapies, inclisiran, ANGPTL3 inhibitors, bempedoic acid, and agents targeting triglycerides) are considered according to the agent-specific criteria in this policy.

    Familial hypercholesterolemia (FH) definition
    DefinitionFamilial hypercholesterolemia (FH) is a genetic disorder causing defective removal of LDL cholesterol from blood, resulting in very high LDL levels and increased risk of atherosclerotic cardiovascular disease.
    Clinical consequenceUntreated high LDL leads to plaque formation and increased risk of heart and blood vessel disease
    Management overviewFirst-line management includes diet, exercise, and statins; non-statin pharmacologic agents are considered when LDL remains elevated or statin intolerance exists

    Policy Revision History and Material Changes

    2026-08-01material_additionLatest

    Added coverage criteria for Lerochol (lerodalcibep-liga), Redemplo (plozasiran), and clarified Tryngolza (olezarsen) requirements including prescriber specialty and combination restrictions; Leqvio age/HoFH indications updated; Evkeeza age and prior-Repatha clarification updated.

    2024-01-01age_indication_update

    Updated multiple agents' age and indication criteria: Leqvio HeFH age lowered to 12 years (later finalized in 2026), Evkeeza age reduced in prior updates, Praluent HeFH age lowered to 8 years, Repatha HeFH/HoFH age requirement clarified to 10 years.

    Policy Summary
    PayerPremera Bluecross
    PolicyPharmacologic Treatment of High Cholesterol
    Policy CodePolicy 5.01.558
    Change TypeAdded multiple agents and revised age/indication criteria
    Effective DateAug 1, 2026
    Last ReviewJul 14, 2026
    Next Review DateJul 14, 2026
    Key ActionObtain prior authorization confirming diagnosis, baseline LDL-C or TG thresholds, and evidence of maximally tolerated statin therapy (or documented statin intolerance) before initiating listed injectable or specialty agents.
    SourceLink
    On This Page
    Coverage Criteria and Medical NecessityPrior Authorization, Documentation, and Billing RequirementsBilling Codes, Thresholds, and Key Numeric CriteriaBackground, Definitions and MechanismsPolicy Revision History and Material Changes

    Quantity limits specified; document prior therapies and genetic/LDL thresholds.

    Different LDL thresholds (eg, >=100 mg/dL) apply for hypercholesterolemia indications per policy.

    LDL-C >=70 or >=100 mg/dL depending on indication

    For HeFH: untreated LDL-C >=190 mg/dL or genetic/clinical criteria; for HoFH: untreated LDL-C >400 mg/dL or treated >=300 mg/dL or genetic confirmation of two mutant alleles.

    Prior biologic trial: Has tried and had inadequate response or intolerance to Repatha (evolocumab) when required by the specific agent (eg, prior biologic trial requirement before Praluent)

    Document prior PCSK9 (Repatha) trial and response.

    Prescriber: Prescribed by or in consultation with a cardiologist, endocrinologist, or clinician focusing on cardiovascular risk management and/or lipid disorders

    Dose limits and formulations per agent (eg, Praluent 150 mg Q2W or 300 mg Q4W).

    Dose limits: evolocumab formulations 140 mg Q2W or 420 mg Q4W; HeFH/HoFH age cutoffs: HeFH >=10 yrs; HoFH >=10 yrs.

    Prescriber: Prescribed by or in consultation with a cardiologist, endocrinologist, or clinician focusing on cardiovascular risk management and/or lipid disorders

    Evolocumab dosing and administration per label; for HoFH dosing may be 420 mg monthly.

    History of and concurrent strict dietary management (<=20 g fat/day, no sugar, no alcohol) AND medication prescribed by or in consultation with an endocrinologist AND medication will not be used in combination with the alternate agent (Redemplo and Tryngolza are mutually exclusive)

    Document dietary management and specialist involvement; do not co-prescribe Redemplo and Tryngolza.

    Step therapy with generic icosapent ethyl required before brand Vascepa for severe HTG.

    exact per label/trials

    Measure LDL-C 4-8 weeks after initiation/titration to assess response; document background therapy.

    ASCVD and/or HeFH with inadequate LDL control or statin intolerance

    Efficacy greatest at week 12; trials included high CV risk, HeFH, and statin-intolerant cohorts.

    Tryngolza (olezarsen): Phase III BALANCE trial in FCS (fasting TG >=880 mg/dL confirmed by genetic testing) showed substantial fasting TG reductions (eg, -43.5% at 6 months; -59.4% at 12 months for 80 mg dose) and reduced acute pancreatitis events versus placeboFasting TG >=880 mg/dL and genetic confirmation of FCS

    BALANCE: randomized 50 mg, 80 mg, or placebo SC q4w for 49 weeks; safety profile acceptable.

  1. J1305 — Injection, evinacumab‑dgnb (Evkeeza) 5 mg.
  2. J1306 — Injection, inclisiran (Leqvio) 1 mg.
  3. J3490 — Unclassified drugs (report Redemplo, Tryngolza).
  4. Billing Rule

    Benefit and code management (medical vs pharmacy benefit)

    Certain injectable agents are managed through the medical benefit while most drugs are managed through the pharmacy benefit; Evkeeza and Leqvio are managed via the medical benefit and Redemplo/Tryngolza may be reported/managed using unclassified drug codes. Prior authorization follows the applicable medical or pharmacy benefit rules.

    • Evkeeza (evinacumab) and Leqvio (inclisiran) are managed through the medical benefit.
    • Redemplo (plozasiran) and Tryngolza (olezarsen) are managed through pharmacy and medical benefit and may be reported with J3490.
    • Prior authorization must be submitted per the benefit assignment (medical vs pharmacy).
    Prior Authorization

    Prior authorization for PCSK9‑targeted therapies and inclisiran

    For PCSK9‑targeted therapies and inclisiran, prior authorization must confirm the diagnosis (HeFH or clinical ASCVD), baseline LDL‑C indicating need for further reduction, and that the member is on maximally tolerated statin therapy (or statin intolerant), consistent with trial entry criteria.

    • Document baseline LDL‑C and that one high‑intensity statin trial (≥8 weeks) was attempted with LDL‑C remaining above policy thresholds OR document statin intolerance.
    • Trials for inclisiran and PCSK9 agents excluded individuals already taking PCSK9 inhibitors, so PA should reflect applicable prior biologic use restrictions.
    Prior Authorization

    Prior authorization: candidate selection (trial‑based)

    Candidate selection for specialty agents should align with pivotal trial inclusion criteria—e.g., Tryngolza candidates had confirmed FCS with fasting triglycerides ≥880 mg/dL and genetic confirmation in trials; use trial criteria to inform who should be considered for PA.

    • Tryngolza (olezarsen) trial enrollment required fasting TG ≥880 mg/dL and genetic confirmation of FCS.
    • Use trial‑derived thresholds and background therapy requirements to identify appropriate candidates for prior authorization.
    Note

    Authorization rule changes and non‑formulary exception duration

    Authorization rules were updated: initial authorization requirements to use certain agents with a high‑intensity statin were removed for some specialty agents, and non‑formulary exception authorizations may be approved up to 12 months.

    • Removed initial authorization requirement to use in combination with a high‑intensity statin for Evkeeza, Juxtapid, Nexletol, and Nexlizet.
    • Non‑formulary exception authorizations for listed drugs may be approved up to 12 months.
    Prior Authorization

    Prior authorization required for listed lipid‑lowering agents

    Prior authorization is required for many listed lipid‑lowering agents; policy history documents additions/removals of HCPCS codes and PA requirements for agents including Leqvio, Repatha, Praluent, Evkeeza, Juxtapid, Nexletol, Nexlizet, and Tryngolza.

    • Submit PA per each agent’s medical necessity criteria; initial approvals generally up to 12 months unless agent‑specific longer periods noted.
    • Refer to policy HCPCS coding history for code changes affecting PA submissions.
    Step Therapy

    Step therapy requirements

    Most therapies require stepwise trials: document a trial of a high‑intensity statin (e.g., atorvastatin 40 mg+ or rosuvastatin 20 mg+) for ≥8 continuous weeks unless statin intolerance is documented; many specialty agents also require prior trial and inadequate response or intolerance to an alternative biologic (e.g., Repatha) where specified.

    • High‑intensity statin trial: atorvastatin ≥40 mg daily or rosuvastatin ≥20 mg daily for at least 8 continuous weeks.
    • Where specified (e.g., Praluent, some Evkeeza/Juxtapid age groups), must document prior inadequate response or intolerance to Repatha (evolocumab).
    Step Therapy

    Required trials and step therapy (PCSK9 biologics)

    For PCSK9 inhibitors and similar biologics, prior to approval the record must show a high‑intensity statin trial (≥8 weeks) with persistent elevated LDL‑C or documented statin intolerance, and where indicated, prior inadequate response or intolerance to the alternative PCSK9 agent (e.g., Repatha vs Praluent).

    • Document LDL‑C remained ≥70 mg/dL (ASCVD/HeFH/HoFH) after high‑intensity statin trial or document statin intolerance per policy definitions.
    • If policy specifies, document trial and inadequate response/intolerance to Repatha before approving Praluent (or vice versa as updated).
    Documentation Required

    Dosing and response assessment

    Dosing guidance: for PCSK9 inhibitors start alirocumab 75 mg SQ every 2 weeks and up‑titrate to 150 mg Q2W if LDL‑C response inadequate; measure LDL‑C 4–8 weeks after initiation or titration to assess response.

    • Measure LDL‑C within 4–8 weeks after initiation/titration to determine need for dose change.
    • Evolocumab dosing examples: 140 mg Q2W or 420 mg monthly depending on indication; provide injections per label.
    Step Therapy

    Step: maximally tolerated statin therapy prior to PCSK9 or inclisiran

    Policy requires patients to be on maximally tolerated statin therapy (with or without other lipid‑modifying therapy) before initiating PCSK9 agents or inclisiran, consistent with trial populations and coverage criteria.

    • Document maximally tolerated statin dose in the medical record.
    • Trials and coverage criteria excluded individuals already taking PCSK9 inhibitors for inclisiran trials—ensure prior biologic status is clear.
    Step Therapy

    Step therapy implication for PCSK9/anti‑PCSK9 biologic

    Step therapy implication: Lerochol and other PCSK9‑like agents were studied in patients already on maximally tolerated statin therapy, implying these agents are for patients needing additional LDL‑C lowering after statin optimization.

    • Ensure documentation shows ongoing maximally tolerated statin therapy when requesting Lerochol or similar PCSK9 agents.
    • Cite trial enrollment details showing requirement for background statin therapy.
    Note

    Step therapy modifications

    Step therapy requirements have been modified historically for certain agents—e.g., Evkeeza and Juxtapid previously required PCSK9 inhibitor trials; updates clarify Repatha is the required prior biologic in specific age groups.

    • Check the updated policy history for agent‑specific step changes (Evkeeza/Juxtapid: Repatha requirement clarified for ages ≥10).
    • Document prior biologic trials per current policy version when submitting PA.
    Step Therapy

    Step therapy and required prior medication trials

    Step therapy and required prior medication trials vary by agent; historically Evkeeza and Juxtapid required trials of PCSK9 inhibitors (updated to Repatha only), and some brand agents require trials of generic alternatives before brand coverage.

    • Document trials of generic alternatives (e.g., generic icosapent ethyl) prior to brand Vascepa when specified.
    • Follow agent‑specific prior therapy sequences in the policy when requesting authorization.
    Documentation Required

    Required documentation for prior authorization (statin trials specifics)

    Required documentation for PA must include evidence of trials of specified high‑intensity statin therapy (e.g., atorvastatin ≥40 mg or rosuvastatin ≥20 mg daily for ≥8 weeks) with LDL‑C values remaining above policy thresholds, or documentation meeting the policy’s statin intolerance definitions.

    • Provide lipid panel results showing LDL‑C before and after statin trial.
    • If claiming statin intolerance, document rhabdomyolysis or muscle symptoms that resolved on discontinuation per policy definitions.
    Documentation Required

    Required documentation — office notes and supporting records

    Submit office visit notes documenting the diagnosis, relevant history, physical exam, lipid panels, and complete medication history to demonstrate medical necessity for the requested agent.

    • Include office notes with diagnosis and rationale linking the patient’s lipid values to the requested therapy.
    • Attach recent lipid panel and medication trial history to the PA submission.
    Documentation Required

    Required medical record elements

    Medical records must show the diagnosis, relevant history/physical exam findings, lipid panel results, and medication history to support that medical necessity criteria are met.

    • Records should include dates and results of statin trials, prior biologic use, and LDL‑C values used to justify therapy.
    • Include specialist consultation notes where required by the policy.
    Documentation Required

    Required clinical documentation (baseline LDL‑C and therapy history)

    Clinical documentation must include baseline LDL‑C and evidence of maximally tolerated statin therapy (or documented statin intolerance) as required for PCSK9‑targeting agents and inclisiran, consistent with trial populations.

    • Baseline LDL‑C value and date.
    • Evidence of statin regimen and duration (e.g., atorvastatin 40 mg daily × ≥8 weeks) or documentation of intolerance.
    Note

    Clinical trial population details (inform operational selection)

    Clinical trial population details (HoFH for Evkeeza; maximally tolerated statin requirement for Lerochol; FCS criteria for Tryngolza) should be used to operationally select candidates and document PA rationale.

    • Evkeeza trial ELIPSE‑HoFH: IV evinacumab 15 mg/kg every 4 weeks in HoFH with LDL‑C reductions ~47%–49%.
    • Lerochol trials required maximally tolerated statin background therapy.
    • Tryngolza trials required fasting TG ≥880 mg/dL and genetic confirmation of FCS.
    Documentation Required

    Tryngolza documentation requirements (genetic testing or qualifying clinical criteria)

    Tryngolza (olezarsen) documentation must include genetic testing or a qualifying clinical diagnosis to confirm familial chylomicronemia syndrome; the policy specifies the drug must be prescribed by or in consultation with an endocrinologist and cannot be used in combination with Redemplo (plozasiran).

    • Confirm FCS with genetic testing or qualifying clinical criteria and fasting TG ≥880 mg/dL per trial evidence.
    • Include endocrinology prescription or consultation documentation and affirm no concurrent Redemplo use.
    Documentation Required

    Specialist prescribing/consultation requirements

    Certain agents require prescribing by or consultation with specific specialists; Tryngolza must be prescribed by or in consultation with an endocrinologist, and other agents (Evkeeza, Juxtapid) require cardiology/endocrinology or lipid specialist involvement per policy. Include specialty consult notes when applicable.

    • Tryngolza: prescribed by or in consultation with an endocrinologist.
    • Evkeeza and Juxtapid: prescribed by or in consultation with a cardiologist, endocrinologist, or physician focused on lipid disorders.
    Denial Risk

    Site‑of‑service denial risk

    If site‑of‑service criteria are not met for outpatient infusion or injection services, the request may be considered not medically necessary and denied; Leqvio is explicitly subject to site‑of‑service review.

    • Outpatient hospital IV infusion department and hospital‑based outpatient settings may be considered not medically necessary if policy SOS criteria are unmet.
    • Leqvio administration location is subject to site‑of‑service review per the policy history and site‑of‑service section.
    Denial Risk

    Investigational / Not Medically Necessary uses

    Use of listed medications for indications not enumerated in the Medical Necessity sections is considered investigational or not medically necessary and may be denied.

    • All uses of agents for non‑listed indications are investigational per the policy.
    • Check the Medical Necessity sections for the allowed indications before submitting PA.
    Denial Risk

    Documentation‑related denial risk

    Insufficient documentation—missing office visit notes, diagnosis, history, lipid panels, or medication history—can trigger denial; ensure the PA includes complete medical records demonstrating criteria are met.

    • Submit office visit notes with diagnosis, relevant history, physical exam, lipid panels, and full medication history.
    • Incomplete records may lead to requests being considered not medically necessary.
    Denial Risk

    Potential denial risk for missing prior therapy documentation

    Failure to document required prior therapy (e.g., lack of evidence of maximally tolerated statin trial or prior biologic trial where required) may result in denial; inclisiran and PCSK9 trials required patients to be on maximally tolerated statin and excluded current PCSK9 users.

    • Document duration and dosing of statin trials (≥8 weeks high‑intensity statin) and LDL‑C values post‑trial.
    • If policy requires prior Repatha use for certain ages/agents, document inadequate response or intolerance to Repatha.
    Note

    No explicit prior auth triggers described here

    No explicit prior authorization triggers or denial conditions are described in the cited chunk for this topic area.

    Denial Risk

    Tryngolza prescriber and combination restrictions

    Tryngolza requests not prescribed by or in consultation with an endocrinologist, or requests proposing concurrent use with Redemplo (plozasiran), may conflict with policy updates and risk denial.

    • Policy states Tryngolza must be prescribed by or in consultation with an endocrinologist and must not be used together with Redemplo.
    • Include endocrinologist consultation documentation and a statement that Redemplo is not being used concurrently.
    Denial Risk

    Benefit limitations may trigger denial

    Coverage is subject to member benefit limitations; services outside member benefit limits or not covered under the member’s contract may be denied—confirm benefit coverage prior to PA submission.

    • Member contracts differ; consult the member benefit booklet or customer service to verify coverage.
    • Policy does not apply to Medicare Advantage members—check plan applicability.
    >= 500 mg/dL (generic icosapent ethyl/Lovaza treatment threshold)
    FCS trial/enrollment contextFasting TG much higher (see FCS-specific thresholds such as >=880 mg/dL) used for FCS agents
    LDL-C thresholds used across indications
    ASCVD / HeFH treatment threshold>= 70 mg/dL (LDL-C remains >=70 mg/dL after high-intensity statin) — used for ASCVD/HeFH/HoFH criteria and step therapy
    Hypercholesterolemia threshold>= 100 mg/dL (used for some hypercholesterolemia coverage, e.g., Repatha hypercholesterolemia criteria)
    HeFH diagnostic untreated threshold>= 190 mg/dL (untreated LDL-C commonly used to define HeFH eligibility)
    HoFH thresholds>300 mg/dL treated LDL-C or >400 mg/dL untreated LDL-C (used to define HoFH treatment eligibility)
    Lipid thresholds (LDL-C, TG, ASCVD risk, CAC score) — examples
    Example LDL-C thresholds>=70 mg/dL (ASCVD/HeFH), >=100 mg/dL (some hypercholesterolemia criteria), >=190 mg/dL (untreated HeFH), >=300 mg/dL treated HoFH, >400 mg/dL untreated HoFH
    Triglyceride examples>=150 mg/dL (Vascepa CV-risk), >=500 mg/dL (severe HTG treatment), >=880 mg/dL (FCS trial/agent enrollment)
    ASCVD risk and CAC examples10-year ASCVD risk >=7.5% or CAC >=100 Agatston units / >=75th percentile used as alternative risk triggers
    LDL-C and total cholesterol diagnostic thresholds (international examples)
    Pediatric diagnostic LDL-C examplesLDL-C >4.0 mmol/L (155 mg/dL) in children (<16 years) meets Simon Broome thresholds
    Adult diagnostic LDL-C exampleLDL-C >4.9 mmol/L (190 mg/dL) in adults (>16 years) meets Simon Broome 'definite' or 'possible' thresholds
    Dutch Lipid Network categoriesDutch criteria include LDL-C categories up to >=8.5 mmol/L (330 mg/dL) for scoring FH likelihood
    Fasting triglyceride threshold for FCS trial enrollment
    FCS trial enrollment TG threshold>= 880 mg/dL (used as fasting TG requirement in the BALANCE Phase III trial of olezarsen)
    FCS diagnostic contextTrial required genetic confirmation of FCS for enrolled participants with fasting TG >=880 mg/dL
    Applicability to coveragePolicy uses >=880 mg/dL as an FCS-specific threshold for Tryngolza/Redemplo candidate selection and coverage documentation
    LDL-C target (historical change example)
    Historical LDL-C target change exampleLDL-C target changed from 100 mg/dL to 70 mg/dL in prior policy revisions (noted in history)
    Context of changeChange reflected in 2019 history notes revising LDL-C target and statin management language
    ImplicationLower LDL-C target (70 mg/dL) is applied in ASCVD/HeFH initiation criteria across subsequent updates
    Site of service (SOS) definition
    DefinitionSite of service (SOS) is the location where a drug is administered (e.g., physician office, infusion center, home infusion, hospital outpatient setting); SOS criteria inform medical benefit review and coverage determinations.
    Policy implicationCertain infusion/injection services may be covered only in specified medically necessary sites for initial dosing or re-initiation (first 90 days) and may be denied if SOS criteria not met
    Examples of SOSPhysician's office, infusion center, home infusion, outpatient hospital IV infusion department, hospital-based outpatient clinical care
    High-intensity statin definition and examples
    High-intensity statin examplesAtorvastatin 40 mg or greater daily; Rosuvastatin 20 mg or greater daily (trial requirement: >=8 continuous weeks)
    Role in step therapyMost advanced therapies require trial of a high-intensity statin for >=8 weeks with persistent LDL-C above policy thresholds unless statin intolerant
    Statin intolerance examplesRhabdomyolysis to one statin; skeletal-muscle related symptoms after trying both rosuvastatin and atorvastatin which resolved upon discontinuation
    Familial Chylomicronemia Syndrome (FCS) criteria definition
    Core FCS criteriaFasting serum triglyceride >=880 mg/dL plus genetic confirmation of mutations affecting LPL activity OR qualifying clinical features (recurrent pancreatitis, hospitalizations, childhood pancreatitis, family history)
    Additional requirementsConcurrent strict dietary management (<=20 g fat/day, no sugar, no alcohol) and prescription by or in consultation with an endocrinologist
    Mutual exclusivityTryngolza (olezarsen) and Redemplo (plozasiran) are not to be used in combination per policy
    Definite Familial Hypercholesterolemia (Simon Broome) definition
    Simon Broome 'Definite' FH criteriaTotal cholesterol >6.7 mmol/L (260 mg/dL) or LDL-C >4.0 mmol/L (155 mg/dL) in a child <16 OR total cholesterol >7.5 mmol/L (290 mg/dL) or LDL-C >4.9 mmol/L (190 mg/dL) in an adult (>16) AND tendon xanthomas in individual or relative OR DNA-based evidence of LDLR/familial defective APOB/PCSK9 mutation
    UsageSimon Broome 'definite' criteria used as an accepted diagnostic standard for FH in coverage determinations
    Relation to policyMeeting 'definite' Simon Broome criteria can satisfy FH diagnostic requirement for agents like Leqvio, Praluent, Lerochol
    Possible/Probable Familial Hypercholesterolemia definition
    Simon Broome 'Possible/Probable' FH criteriaTotal cholesterol >6.7 mmol/L (260 mg/dL) or LDL-C >4.0 mmol/L (155 mg/dL) in a child <16 OR total cholesterol >7.5 mmol/L (290 mg/dL) or LDL-C >4.9 mmol/L (190 mg/dL) in an adult (>16) AND family history of premature MI (relative age thresholds) OR family history of raised cholesterol in relatives
    Role in coverage'Possible/Probable' Simon Broome classification is accepted for FH diagnostic pathways in the policy where specified
    Alternative diagnosticsDutch Lipid Network scoring or genetic confirmation are alternative accepted methods
    Leqvio (inclisiran) mechanism and dosing summary
    MechanismLeqvio (inclisiran) is a small interfering RNA (siRNA) that inhibits PCSK9 mRNA, reducing PCSK9 and lowering LDL-C
    Dosing summary284 mg subcutaneously as a single injection at Day 1 (onset), again at 3 months, then every 6 months thereafter
    Monitoring noteLDL-C lowering may be measured as early as 30 days after initiation; assess LDL-C when clinically indicated
    Nexletol (bempedoic acid) definition
    Definition and mechanismNexletol (bempedoic acid) is an oral prodrug that inhibits ATP-citrate lyase (ACL), reducing cholesterol synthesis upstream of HMG-CoA reductase
    ActivationActivated in the liver to its active metabolite (bempedoyl-CoA), leading to upregulation of LDL receptors without activation in skeletal muscle
    Dose limit in policyDose limited to 180 mg bempedoic acid daily for Nexletol/Nexlizet indications
    Vascepa (icosapent ethyl) definition
    Definition and mechanismVascepa (icosapent ethyl) is an ethyl ester of EPA that reduces VLDL-C and triglyceride synthesis/secretion and increases TG clearance
    Dose limitDose limited to 4 grams per day (four 0.5-g capsules twice daily or two 1-g capsules twice daily)
    Indications in policyUsed for cardiovascular risk reduction (TG >=150 mg/dL on statin with CVD or diabetes+2 risk factors) and for severe HTG (TG >=500 mg/dL after trial of fibrate/niacin)
    ANGPTL3 inhibitor / evinacumab (Evkeeza) definition
    Definition and mechanismEvkeeza (evinacumab-dgnb) is an ANGPTL3 inhibitor (monoclonal antibody) that increases LPL activity and lowers LDL-C and TG; shown effective in HoFH
    Pediatric/age notePolicy updated age requirement to 1 year or older for Evkeeza; for ages >=10 years, trial of Repatha is clarified first
    Dose limit in policyDose limited to 15 mg/kg IV every 4 weeks for Evkeeza in HoFH
    Bempedoic acid / Nexletol definition
    DefinitionBempedoic acid (Nexletol) is an oral ACL inhibitor prodrug activated in the liver that lowers LDL-C without activity in skeletal muscle
    Clinical roleUsed as add-on to maximally tolerated statin therapy or in statin-intolerant patients for LDL-C lowering across ASCVD/HeFH/hypercholesterolemia indications
    Dose limitPolicy dose limit 180 mg/day
    Olezarsen / Tryngolza definition
    Definition and mechanismOlezarsen (Tryngolza) is a GalNAc-conjugated antisense oligonucleotide targeting apoC-III mRNA to reduce serum apoC-III and lower triglycerides in FCS
    FDA-approved useApproved as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS)
    Trial evidencePhase III BALANCE enrolled adults with fasting TG >=880 mg/dL and genetically confirmed FCS showing substantial TG reductions with 80 mg dosing
    FCS clinical definition
    Clinical definitionFamilial chylomicronemia syndrome (FCS) is a genetic disorder causing severe hypertriglyceridemia and recurrent pancreatitis; diagnosis may be confirmed by genetic testing or qualifying clinical criteria
    Policy enrollment thresholdPolicy requires fasting TG >=880 mg/dL plus genetic or clinical confirmation for Tryngolza/Redemplo coverage
    Management requirementsConcurrent strict dietary management and endocrinology involvement are required for coverage
    HeFH / HoFH definitions usage note
    Usage noteHeFH (heterozygous) and HoFH (homozygous) diagnostic classifications are used throughout the policy to determine eligibility for therapies like Leqvio, Praluent, Repatha, Evkeeza
    Age updatesPolicy history documents age threshold changes (e.g., HeFH ages lowered for some agents; Leqvio HeFH age lowered to >=12 years)
    Diagnostic optionsPolicy accepts genetic confirmation, Simon Broome, or Dutch Lipid Network scores as evidence for FH diagnosis depending on agent-specific criteria
    2026-08-01age_indication_updateLatest

    Finalized updates to Leqvio (inclisiran) changing HeFH age requirement to 12 years and added HoFH coverage; clarified Evkeeza pediatric age and Repatha trial sequencing for older children.

    2024-01-01step_therapy_modification

    Updated step therapy for Evkeeza and Juxtapid to require Repatha (evolocumab) rather than both Praluent and Repatha in prior rules.

    2026-08-01step_therapy_modificationLatest

    Clarified prior biologic/step requirements across agents including explicit Repatha-first sequencing for certain pediatric age groups and historic removal of some initial authorization requirements.

    2025-01-01removal

    Removed Lescol (fluvastatin) from the policy as discontinued (2025 update).

    2026-08-01removalLatest

    Removed coverage criteria for multiple discontinued products (Altoprev, Antara, Fenoglide, Niaspan, Pravachol, Triglide, Trilipix) and removed references to non-formulary exception reviews.

    2026-08-01coverage_stance_and_agent_specific_additionsLatest

    Policy restated general coverage-with-criteria stance and added agent-specific criteria effective 2026-08-01, including Lerochol and Redemplo additions and specific prescriber and diagnostic requirements for Tryngolza.